![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Precision BioLogic’s Factor IX Assay Cleared for Hemophilia B
Precision BioLogic’s Factor IX Assay Cleared for Hemophilia B
Precision BioLogic’s CRYOcheck Chromogenic Factor IX assay has gained FDA clearance for identifying factor IX deficiency in plasma — an indicator of hemophilia B, a rare genetic bleeding disorder.
The assay, which changes color to indicate result levels, is the first available in the U.S. for factor IX, a protein needed for blood clotting to seal a wound and promote healing.
Nova Scotia-based Precision BioLogic launched the assay in Canada, the EU, UK, Australia, and New Zealand in 2022. The company previously released a chromogenic assay for factor VIII for diagnosis of hemophilia A in 2020.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct